Participating Faculty: Combination Therapy in Pulmonary Arterial Hypertension: Is This the New Standard of Care?

Faculty

Gary M. Besinque, PharmD

Pharmacist Evidence Analyst and Strategist

Drug Information Services—California Regions

Kaiser Permanente

Downey, California

Adjunct Assistant Professor of Clinical Pharmacy

University of Southern California School of Pharmacy

Los Angeles, California

Cassandra A. Lickert, MD

Senior Medical Liaison

Medical Managed Markets, Health Economics and Outcomes Research

Actelion Pharmaceuticals US, Inc

South San Francisco, California

Susan Raspa, RN, BSN

Senior Medical Liaison

Medical Managed Markets, Health Economics and Outcomes Research

Actelion Pharmaceuticals US, Inc

South San Francisco, California

George Ruiz, MD, MBA

Director

Pulmonary Hypertension Program

Medstar Heart Institute

Washington, DC

Acknowledgment: Faculty wishes to acknowledge the contributions and editorial support of Janis Pruett, RN, MSN, EdD, CDE, FNP-BC.

Faculty Disclosures

These faculty report relationships with the following organizations:

Cassandra A. Lickert, MD

Employment and stock ownership: Actelion Pharmaceuticals US, Inc

Susan Raspa, RN, BSN

Employment and stock ownership: Actelion Pharmaceuticals US, Inc

George Ruiz, MD, MBA

Speakers bureau: Actelion Pharmaceuticals US, Inc; United Therapeutics

Gary M. Besinque, PharmD, reports no relationships or financial interests with any entity that would pose a conflict of interest with the subject matter of this supplement.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Pulmonary arterial hypertension (PAH) is a rare, progressive, and potentially fatal cardiopulmonary syndrome that imposes a substantial burden both on patients in terms of morbidity and mortality and on managed care organizations in terms of resource utilization. This supplement to The American Journal of Managed Care presents managed care decision makers with information and evolving clinical evidence in support of the potential for combination therapy to become the standard of care for patients with PAH.

Download PDF: Participating Faculty: Combination Therapy in Pulmonary Arterial Hypertension: Is This the New Standard of Care?